Nicergoline


Ergoline derivative / alpha-1 antagonist + cerebrovascular agent

A semisynthetic ergoline derivative; an alpha-1 adrenergic antagonist with cerebrovascular and acetylcholinesterase modulatory activity.

Abstract

Nicergoline (10-alpha-methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; CAS 27848-84-6; molecular formula C24H26BrN3O3; molecular weight 484.39) is a semisynthetic ergoline developed at Farmitalia (Italy) and approved in several European countries under the trade name Sermion for cerebrovascular disease and age-related cognitive decline. Mechanism: alpha-1 adrenergic antagonism (cerebrovascular dilation), inhibition of platelet aggregation, weak nicotinic and muscarinic effects, and modulation of acetylcholinesterase activity in some studies. Plasma half-life is approximately 2 hours for the parent compound; the active metabolite 1,6-dimethyl-8-beta-hydroxymethyl-10-alpha-methoxy-ergoline (MMDL) has substantially longer half-life. Approved for cerebrovascular insufficiency in Europe; not approved in the US. Used as a reference ergoline cerebrovascular agent in research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph